Time filter

Source Type

Ueda S.,Ohyodo General Hospital | Ueda S.,Nara Prefecture General Medical Center | Minami Y.,Ohyodo General Hospital | Hara Y.,Ohyodo General Hospital | Nakamura T.,Nara Prefecture General Medical Center
Japanese Journal of Cancer and Chemotherapy | Year: 2014

We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period. In September 2007, distal gastrectomy was performed for treating gastric cancer with synchronous peritoneal dissemination in a 78-year-old man. Combination chemotherapy of S-1 and CDDP was administered after the surgical procedure. Following the completion of 9 courses, this regimen was discontinued owing to adverse events; therefore, S-1 (40-50 mg/body/day) or capecitabine (1,800 mg/body/day) chemotherapy was initiated. S-1 or capecitabine were orally administered for 2 weeks, followed by a 2-week or 1-week interval, respectively; this regimen was continued for over 5 years. The patient died in June 2013.

Ueda S.,Ohyodo General Hospital | Minami Y.,Ohyodo General Hospital | Hara Y.,Ohyodo General Hospital | Kawano T.,Ohyodo General Hospital | Tominaga T.,Ohyodo General Hospital
Japanese Journal of Cancer and Chemotherapy | Year: 2011

We report a case of synchronous multiple liver metastases of rectal cancer successfully treated with tegafur/uracil (UFT) and oral Leucovorin (LV) chemotherapy. Lower anterior resection was carried out on the rectal cancer patient (an 80-year-old man), who had synchronous multiple liver metastases. The UFT (450 mg/day) and oral LV (75 mg/day) were orally administered for 4 weeks, followed by a 1-week interval after the surgical procedure. After completion of 16 courses, CT scan showed no liver metastases, and the patient was judged to have achieved a complete response (CR). The interval of CR was maintained for sixteen months until the age of 82. This chemotherapy is expected to have a potent therapeutic efficacy for older adult patients with advanced rectal cancer, because it is convenient and causes no severe diverse events.

Discover hidden collaborations